Protocol Ledger

NCT07440290 · Phase II/III · RECRUITING

DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.

Interventional Phase II/III clinical trial protocol NCT07440290 sponsored by Cancer Research UK in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-04-01 Enrollment: 30 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07440290
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)30 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07440290
Protocol FieldVerified Registry Value
NCT IdentifierNCT07440290
Consolidated Lead SponsorCancer Research UK
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment30 participants (ESTIMATED)
Registered Start Date2026-04-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07440290
Hospital Research SiteLocationSite Profile
Addenbrooke's HospitalCambridge, United KingdomOpen Hospital Dossier ->
Western General HospitalEdinburgh, United KingdomOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI